155 related articles for article (PubMed ID: 24453924)
1. Reducing agents decrease the oxidative burst and improve clinical outcomes in COPD patients: a randomised controlled trial on the effects of sulphurous thermal water inhalation.
Contoli M; Gnesini G; Forini G; Marku B; Pauletti A; Padovani A; Casolari P; Taurino L; Ferraro A; Chicca M; Ciaccia A; Papi A; Pinamonti S
ScientificWorldJournal; 2013; 2013():927835. PubMed ID: 24453924
[TBL] [Abstract][Full Text] [Related]
2. Sulphurous thermal water inhalation impacts respiratory metabolic parameters in heavy smokers.
Carubbi C; Masselli E; Calabrò E; Bonati E; Galeone C; Andreoli R; Goldoni M; Corradi M; Sverzellati N; Pozzi G; Banchini A; Pastorino U; Vitale M
Int J Biometeorol; 2019 Sep; 63(9):1209-1216. PubMed ID: 31227888
[TBL] [Abstract][Full Text] [Related]
3. Effects of inhalation of thermal water on exhaled breath condensate in chronic obstructive pulmonary disease.
Guarnieri G; Ferrazzoni S; Scarpa MC; Lalli A; Maestrelli P
Respiration; 2010; 79(3):216-21. PubMed ID: 19590158
[TBL] [Abstract][Full Text] [Related]
4. Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients.
Brindicci C; Ito K; Torre O; Barnes PJ; Kharitonov SA
Chest; 2009 Feb; 135(2):353-367. PubMed ID: 18719059
[TBL] [Abstract][Full Text] [Related]
5. Effect of inhalation of thermal water on airway inflammation in chronic obstructive pulmonary disease.
Pellegrini M; Fanin D; Nowicki Y; Guarnieri G; Bordin A; Faggian D; Plebani M; Saetta M; Maestrelli P
Respir Med; 2005 Jun; 99(6):748-54. PubMed ID: 15878492
[TBL] [Abstract][Full Text] [Related]
6. Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease.
Votto JJ; Bowen JB; Barton RW; Thrall RS
J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):329-34. PubMed ID: 18800883
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an educational intervention in primary health care in inhalation techniques: study protocol for a pragmatic cluster randomised controlled trial.
Leiva-Fernández J; Vázquez-Alarcón RL; Aguiar-Leiva V; Lobnig-Becerra M; Leiva-Fernández F; Barnestein-Fonseca P
Trials; 2016 Mar; 17(1):144. PubMed ID: 26988095
[TBL] [Abstract][Full Text] [Related]
8. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
9. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.
Donohue JF; Ganapathy V; Bollu V; Stensland MD; Nelson LM
Clin Ther; 2017 Jan; 39(1):66-74. PubMed ID: 28011247
[TBL] [Abstract][Full Text] [Related]
10. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease.
Foschino Barbaro MP; Carpagnano GE; Spanevello A; Cagnazzo MG; Barnes PJ
Int J Immunopathol Pharmacol; 2007; 20(4):753-63. PubMed ID: 18179748
[TBL] [Abstract][Full Text] [Related]
11. Sulphurous-arsenical-ferruginous (thermal) water inhalations reduce nasal respiratory resistance and improve mucociliary clearance in patients with chronic sinonasal disease: preliminary outcomes.
Staffieri A; Abramo A
Acta Otolaryngol; 2007 Jun; 127(6):613-7. PubMed ID: 17503230
[TBL] [Abstract][Full Text] [Related]
12. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant effect of sulphurous thermal water on human neutrophil bursts: chemiluminescence evaluation.
Braga PC; Sambataro G; Dal Sasso M; Culici M; Alfieri M; Nappi G
Respiration; 2008; 75(2):193-201. PubMed ID: 17804898
[TBL] [Abstract][Full Text] [Related]
15. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
16. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial.
Gregoriano C; Dieterle T; Breitenstein AL; Dürr S; Baum A; Maier S; Arnet I; Hersberger KE; Leuppi JD
Respir Res; 2018 Dec; 19(1):237. PubMed ID: 30509268
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide and exhaled breath nitrite/nitrates in chronic obstructive pulmonary disease patients.
Liu J; Sandrini A; Thurston MC; Yates DH; Thomas PS
Respiration; 2007; 74(6):617-23. PubMed ID: 17643055
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients.
Wang ST; Bao C; He Y; Tian X; Yang Y; Zhang T; Xu KF
QJM; 2020 Dec; 113(12):870-875. PubMed ID: 32407476
[TBL] [Abstract][Full Text] [Related]
19. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
